<SEC-DOCUMENT>0000200406-25-000082.txt : 20250219 <SEC-HEADER>0000200406-25-000082.hdr.sgml : 20250219 <ACCEPTANCE-DATETIME>20250219173750 ACCESSION NUMBER: 0000200406-25-000082 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250215 FILED AS OF DATE: 20250219 DATE AS OF CHANGE: 20250219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wengel Kathryn E CENTRAL INDEX KEY: 0001745955 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25641967 MAIL ADDRESS: STREET 1: JOHNSON & JOHNSON STREET 2: ONE JOHNSON & JOHNSON PLAZA CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 </SEC-HEADER> <DOCUMENT> <TYPE>4 <SEQUENCE>1 <FILENAME>wk-form4_1740004664.xml <DESCRIPTION>FORM 4 <TEXT> <XML> <?xml version="1.0"?> <ownershipDocument> <schemaVersion>X0508</schemaVersion> <documentType>4</documentType> <periodOfReport>2025-02-15</periodOfReport> <notSubjectToSection16>0</notSubjectToSection16> <issuer> <issuerCik>0000200406</issuerCik> <issuerName>JOHNSON & JOHNSON</issuerName> <issuerTradingSymbol>JNJ</issuerTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001745955</rptOwnerCik> <rptOwnerName>Wengel Kathryn E</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerStreet1>ONE JOHNSON & JOHNSON PLAZA</rptOwnerStreet1> <rptOwnerStreet2></rptOwnerStreet2> <rptOwnerCity>NEW BRUNSWICK</rptOwnerCity> <rptOwnerState>NJ</rptOwnerState> <rptOwnerZipCode>08933</rptOwnerZipCode> <rptOwnerStateDescription></rptOwnerStateDescription> </reportingOwnerAddress> <reportingOwnerRelationship> <isDirector>0</isDirector> <isOfficer>1</isOfficer> <isTenPercentOwner>0</isTenPercentOwner> <isOther>0</isOther> <officerTitle>EVP, Chief TO and Risk Officer</officerTitle> </reportingOwnerRelationship> </reportingOwner> <aff10b5One>0</aff10b5One> <nonDerivativeTable></nonDerivativeTable> <derivativeTable> <derivativeTransaction> <securityTitle> <value>Employee Stock Options (Right to Buy)</value> </securityTitle> <conversionOrExercisePrice> <value>156.15</value> </conversionOrExercisePrice> <transactionDate> <value>2025-02-15</value> </transactionDate> <transactionCoding> <transactionFormType>4</transactionFormType> <transactionCode>A</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>30841</value> </transactionShares> <transactionPricePerShare> <value>0</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <exerciseDate> <footnoteId id="F1"/> </exerciseDate> <expirationDate> <value>2035-02-15</value> </expirationDate> <underlyingSecurity> <underlyingSecurityTitle> <value>Common Stock</value> </underlyingSecurityTitle> <underlyingSecurityShares> <value>30841</value> </underlyingSecurityShares> </underlyingSecurity> <postTransactionAmounts> <sharesOwnedFollowingTransaction> <value>30841</value> </sharesOwnedFollowingTransaction> </postTransactionAmounts> <ownershipNature> <directOrIndirectOwnership> <value>D</value> </directOrIndirectOwnership> </ownershipNature> </derivativeTransaction> <derivativeTransaction> <securityTitle> <value>Restricted Share Units</value> </securityTitle> <conversionOrExercisePrice> <footnoteId id="F2"/> </conversionOrExercisePrice> <transactionDate> <value>2025-02-15</value> </transactionDate> <transactionCoding> <transactionFormType>4</transactionFormType> <transactionCode>A</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionAmounts> <transactionShares> <value>1903</value> </transactionShares> <transactionPricePerShare> <value>0</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <exerciseDate> <footnoteId id="F2"/> </exerciseDate> <expirationDate> <footnoteId id="F2"/> </expirationDate> <underlyingSecurity> <underlyingSecurityTitle> <value>Common Stock</value> </underlyingSecurityTitle> <underlyingSecurityShares> <value>1903</value> </underlyingSecurityShares> </underlyingSecurity> <postTransactionAmounts> <sharesOwnedFollowingTransaction> <value>1903</value> </sharesOwnedFollowingTransaction> </postTransactionAmounts> <ownershipNature> <directOrIndirectOwnership> <value>D</value> </directOrIndirectOwnership> </ownershipNature> </derivativeTransaction> </derivativeTable> <footnotes> <footnote id="F1">Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.</footnote> <footnote id="F2">Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.</footnote> </footnotes> <remarks></remarks> <ownerSignature> <signatureName>/s/ Laura H. McFalls, as attorney-in-fact for Kathryn E. Wengel</signatureName> <signatureDate>2025-02-19</signatureDate> </ownerSignature> </ownershipDocument> </XML> </TEXT> </DOCUMENT> </SEC-DOCUMENT>